Ryman Healthcare (ASX:RYM) just released its FY26 results and it could be succeeding where others failed

Ryman’s EBITDAF nearly doubled to NZ$88m and the FY28 dividend pathway just stopped looking theoretical

Ryman Healthcare (ASX:RYM) has delivered the kind of FY26 result that turnaround investors wait years to see. The company’s Free cash flow turned positive for the first time in over a decade, landing at NZ$188 million and its EBITDAF nearly doubled to NZ$88 million on revenue up 10% to NZ$849 million.

For a stock that dual-listed on the ASX only last October and arrived with the baggage of the entire Australian aged care sector behind it, that is a meaningful shift. Ryman is no longer the cash-burning developer chasing its own balance sheet. It is starting to look like an operator throwing off real money.

The company’s gearing now sits at 27.8%, the lowest in the sector, with no bank maturities until FY31. Management has flagged a return to sustainable dividends in FY28, subject to operating performance and Board approval.

We think this result moves Ryman from a balance sheet recovery story to an earnings recovery story. Those tend to be valued very differently by the market.

The cash flow line is the only number that really mattered today

Ryman has spent a decade building villages faster than it could fund them from internal cash. The NZ$188 million positive free cash flow result breaks that pattern.

The drivers were not magic. Development capex came in below guidance at NZ$159.5 million, land divestments delivered NZ$72 million, and cash release from completed inventory ran at NZ$150 million. Ryman is essentially shrinking its construction footprint and harvesting what it already built.

Management lifted the land divestment target from NZ$200 million to roughly NZ$250 million, with NZ$147 million already settled or contracted including today’s A$30.9 million Kealba sale.

Aged care economics are doing the heavy lifting now

The bull case for Ryman has always rested on its integrated care model surviving where pure-play operators like Estia and Japara could not. Aged care EBITDAF per bed hit NZ$17.7k in FY26, and FY27 guidance targets NZ$20-25k per bed.

That uplift comes from filling new capacity, growing aged care premiums, and getting more retirement living residents onto the new pricing terms introduced over the reset.

The skeptical read is that aged care reform across both sides of the Tasman remains a moving target, and funding has historically lagged cost. We would want to see another two quarters of margin expansion before declaring the operating model fully fixed.

Retirement living is still the soft spot in the FY27 setup

FY27 year-to-date retirement living resales and net contracts are described as broadly flat, with serviced apartments taking a higher mix share. That is code for the independent living market remaining sluggish.

Build rate guidance drops sharply to 157-168 units from 330 in FY26. The strategy is now to sell what exists rather than build more.

FY27 earnings growth has to come from aged care margins and cost out, not retirement living velocity. The NZ$47 million of the NZ$150 million sustainable cash flow improvement target was delivered in FY26, leaving NZ$103 million to find over the next three years.

The FY28 dividend signal is now the number to track

Ryman’s FY26 result is the strongest evidence yet that the integrated retirement living and aged care model can generate cash at scale. The graveyard of ASX-listed aged care stocks is long, and we covered the broader question of whether Ryman could buck that trend in our earlier piece at stocksdownunder. Today’s numbers push the answer closer to yes.

The 80+ population doubling by 2050 is the demographic tailwind that does the work for management if the operating model is fixed. If FY27 lands inside guidance and the FY28 dividend signal holds, the NTA discount the Chair flagged becomes very hard to defend through FY28.